Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalant Doses for Cardioversion in AF Ablation
NCT04209959Phase 4Unknown
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nifekalant in Atrial fibrillation (AFib), sponsored by The Second Affiliated Hospital of Nanchang University. Status: unknown.
02
Drugs
nifekalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04209959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209959.